Verona Initiates P-III ENHANCE Studies Evaluating Nebulized Ensifentrine for the Maintenance Treatment of COPD

 Verona Initiates P-III ENHANCE Studies Evaluating Nebulized Ensifentrine for the Maintenance Treatment of COPD

Shots:

  • The two P-III studies (ENHANCE-1 & ENHANCE-2) will assess the efficacy and safety of nebulized ensifentrine (3mg, bid) as monothx. and added onto a single bronchodilator either a LAMA/ LABA vs PBO in ~800 patients with mod. to sev. COPD at sites primarily in the US and EU for 24wks. & 48wks. respectively
  • The 1EPs will be the improvement in lung function as measured by FEV1 over 12hrs. following 12wks. of treatment while 2EPs will be COPD symptoms and health-related QoL through 24wks. Additional lung function endpoints including peak and morning trough FEV1 will also be assessed
  • If successful, the data will support the NDA submission to the US FDA. Ensifentrine is a first-in-class therapy that combines bronchodilator and anti-inflammatory activities in one compound

Click here ­to­ read full press release/ article | Ref: Verona | Image: Share Talk

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post